Viveve Medical, Inc. (VIVE) Receives Consensus Rating of “Buy” from Brokerages
Viveve Medical, Inc. (NASDAQ:VIVE) has received a consensus recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $10.50.
A number of equities research analysts recently issued reports on the stock. Mizuho began coverage on shares of Viveve Medical in a research note on Thursday. They issued a “buy” rating on the stock. Cowen and Company set a $11.00 target price on shares of Viveve Medical and gave the stock a “buy” rating in a research note on Monday, October 23rd. ValuEngine cut shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a research note on Monday, August 14th. Finally, Maxim Group reaffirmed a “buy” rating and set a $11.00 target price on shares of Viveve Medical in a research note on Friday, August 11th.
In other Viveve Medical news, CFO Scott Durbin bought 5,000 shares of the stock in a transaction on Wednesday, August 23rd. The shares were bought at an average price of $5.25 per share, with a total value of $26,250.00. Following the purchase, the chief financial officer now directly owns 11,568 shares in the company, valued at approximately $60,732. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 35.10% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Rhumbline Advisers acquired a new position in shares of Viveve Medical during the 2nd quarter valued at about $110,000. JPMorgan Chase & Co. acquired a new position in shares of Viveve Medical during the 2nd quarter valued at about $151,000. Virtu KCG Holdings LLC acquired a new position in shares of Viveve Medical during the 2nd quarter valued at about $169,000. Granahan Investment Management Inc. MA boosted its position in shares of Viveve Medical by 32.6% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 102,147 shares of the company’s stock valued at $535,000 after acquiring an additional 25,097 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. acquired a new position in shares of Viveve Medical during the 2nd quarter valued at about $189,000. 65.55% of the stock is currently owned by hedge funds and other institutional investors.
Viveve Medical (NASDAQ VIVE) traded up $0.05 during trading hours on Thursday, hitting $4.81. 129,047 shares of the stock traded hands, compared to its average volume of 186,733. The company has a quick ratio of 3.63, a current ratio of 3.89 and a debt-to-equity ratio of 2.72. Viveve Medical has a 52-week low of $3.75 and a 52-week high of $11.16.
Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.08). Viveve Medical had a negative net margin of 257.58% and a negative return on equity of 275.77%. The company had revenue of $4.07 million during the quarter, compared to analyst estimates of $4.10 million. During the same period in the prior year, the business posted ($0.46) EPS. Viveve Medical’s revenue was up 120.1% compared to the same quarter last year. analysts expect that Viveve Medical will post -2 earnings per share for the current fiscal year.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Stock Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related stocks with our FREE daily email newsletter.